Please provide your email address to receive an email when new articles are posted on . The initial 90‐day window after ACS represents a vulnerable period for recurrent events, possibly attributable ...
The likelihood of recurrent embolic events after percutaneous closure of patent foramen ovale (PFO) is low and unrelated to a residual shunt in the vast majority of cases, according to results of a ...
In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organization Conference (ESOC 2024), anti-inflammatory treatment with long-term colchicine did not reduce ...
(UPDATED) The American College of Cardiology/American Heart Association (ACC/AHA) criteria to identify vascular patients at the highest risk for recurrent cardiovascular events appears to have limited ...
Basel, Switzerland: In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results